TGF-beta Signaling in CBS/PSP

TGF-beta Signaling in CBS/PSP

Overview

Transforming Growth Factor-beta (TGF-β) signaling represents a critical pathway in regulating neuroinflammation, neurogenesis, and cellular survival in the adult brain. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4-repeat (4R) tauopathies, dysregulation of TGF-β signaling contributes to the progressive neurodegeneration characteristic of these disorders. This section examines the role of TGF-β pathway alterations in CBS/PSP pathogenesis and explores therapeutic implications. [@dickson2020]

CBS and PSP share common pathological features of 4R tau accumulation, but exhibit distinct clinical presentations [1](https://doi.org/10.1016/S1474-4422(22)00087-0). While CBS presents with asymmetric cortical dysfunction and basal ganglia degeneration leading to apraxia, alien limb phenomena, and cortical sensory loss, PSP is characterized by vertical gaze palsy, postural instability, and axial rigidity with progressive gait disturbance. TGF-β signaling interacts with tau pathology through multiple mechanisms, including regulation of tau phosphorylation, modulation of neuroinflammation, and control of neuronal survival pathways. Understanding these interactions may reveal novel therapeutic targets for disease modification. [@armstrong2020]

TGF-beta Signaling in CBS/PSP

Overview

Transforming Growth Factor-beta (TGF-β) signaling represents a critical pathway in regulating neuroinflammation, neurogenesis, and cellular survival in the adult brain. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4-repeat (4R) tauopathies, dysregulation of TGF-β signaling contributes to the progressive neurodegeneration characteristic of these disorders. This section examines the role of TGF-β pathway alterations in CBS/PSP pathogenesis and explores therapeutic implications. [@dickson2020]

CBS and PSP share common pathological features of 4R tau accumulation, but exhibit distinct clinical presentations [1](https://doi.org/10.1016/S1474-4422(22)00087-0). While CBS presents with asymmetric cortical dysfunction and basal ganglia degeneration leading to apraxia, alien limb phenomena, and cortical sensory loss, PSP is characterized by vertical gaze palsy, postural instability, and axial rigidity with progressive gait disturbance. TGF-β signaling interacts with tau pathology through multiple mechanisms, including regulation of tau phosphorylation, modulation of neuroinflammation, and control of neuronal survival pathways. Understanding these interactions may reveal novel therapeutic targets for disease modification. [@armstrong2020]

The TGF-β pathway's complex role in neurodegeneration reflects its pleiotropic nature—a single pathway can exert both protective and harmful effects depending on cellular context, ligand concentration, and disease stage. This complexity makes TGF-β an attractive but challenging therapeutic target. [@litvan2020]

The TGF-beta Signaling Pathway

Ligands and Receptors

The TGF-β family includes multiple ligands and receptors with distinct functions [2](https://doi.org/10.1016/j.neuroscience.2018.04.012): [@boxer2020]

TGF-β Isoforms: [@kovacs2022]

• TGF-β1: Ubiquitously expressed, major isoform in the brain
• TGF-β2: Expressed in neurons and astrocytes
• TGF-β3: Expressed during development and in specific brain regions

• Type I receptors (ALK1, ALK5): Serine/threonine kinase receptors that phosphorylate Smad proteins
• Type II receptors (TβRII): Constitutively active kinase receptors that initiate signaling
• Type III receptors (betaglycan): Co-receptors that enhance ligand presentation

Smad Signaling Cascade

The canonical TGF-β pathway signals through Smad proteins: [@chahine2020]

Receptor-activated Smads (R-Smads): Smad2 and Smad3 mediate canonical TGF-beta signaling, while Smad1/5/8 mediate BMP signaling [@jellinger2020]

Co-Smad: Smad4 partners with R-Smads to form transcriptional complexes that translocate to the nucleus [@mandelkow2010]

Inhibitory Smads: Smad6 and Smad7 provide negative feedback by blocking R-Smad phosphorylation and promoting receptor degradation

Non-Canonical Pathways

TGF-β also signals through non-Smad pathways:

• MAPK pathways: Activation of ERK, JNK, and p38
• PI3K/AKT: Pro-survival signaling
• Rho GTPases: Cytoskeletal regulation
• FAK: Focal adhesion kinase activation

TGF-beta in Normal Brain Function

Neuroprotection

TGF-β signaling exerts neuroprotective effects through multiple mechanisms [3](https://doi.org/10.1016/j.neuroscience.2018.04.012):

These protective effects make TGF-β essential for neuronal survival in the adult brain, particularly in regions susceptible to neurodegenerative processes.

Neuroinflammation Modulation

TGF-β plays a dual, context-dependent role in neuroinflammation [4](https://doi.org/10.1038/nrn2297):

• Pro-inflammatory at low levels: Low TGF-β can promote microglial activation and cytokine production
• Anti-inflammatory at high levels: High TGF-β suppresses pro-inflammatory cytokine production and promotes an anti-inflammatory microglial phenotype (M2-like)
• Astrocyte regulation: Controls reactive astrogliosis and scar formation after injury
• T-cell regulation: Modulates adaptive immune responses in the CNS

Neurogenesis

TGF-β signaling regulates adult neurogenesis through [5](https://doi.org/10.1016/j.tins.2020.09.004):

• Subventricular zone: Modulates neural stem cell proliferation and differentiation
• Hippocampal dentate gyrus: Influences granule cell neurogenesis
• Oligodendrogenesis: Guides oligodendrocyte precursor cell differentiation
• Synaptic plasticity: Affects synaptic formation and function

Glial Function

TGF-β signaling regulates all major glial cell types:

• Astrocytes: Controls reactivity, scar formation, and metabolic support
• Microglia: Modulates activation state and inflammatory responses
• Oligodendrocytes: Regulates differentiation and myelination
• Schwann cells: Peripheral nervous system support

TGF-beta Dysregulation in CBS/PSP

Altered Pathway Activity

Studies demonstrate TGF-β pathway alterations in CBS/PSP [6](https://doi.org/10.1007/s00401-020-02171-5):

The motor cortex and basal ganglia, regions prominently affected in CBS, show particular TGF-β pathway alterations. Immunohistochemical studies demonstrate increased TGF-β1 immunoreactivity in glial cells surrounding tau-positive neurons.

Relationship to Tau Pathology

TGF-β signaling interacts with tau pathology in complex and sometimes contradictory ways [7](https://doi.org/10.1186/s40478-014-0012-0):

• Bidirectional regulation: TGF-β can both promote and inhibit tau pathology depending on context
• GSK3β cross-talk: TGF-β signaling modulates GSK3β activity, a key tau kinase
• Neuronal vulnerability: Impaired TGF-β signaling increases susceptibility to tau-induced death
• Neuroinflammation amplification: TGF-β dysregulation amplifies inflammatory responses to tau

Regional Vulnerability

The pattern of TGF-β dysregulation in CBS/PSP follows the regional distribution of tau pathology:

• Motor cortex: Severe TGF-β pathway impairment in CBS
• Basal ganglia: Altered signaling in both CBS and PSP
• Brainstem: Moderate changes in PSP
• Substantia nigra: Loss of neuroprotective signaling contributes to dopaminergic vulnerability

Therapeutic Implications

TGF-beta Pathway Modulation

Therapeutic strategies targeting TGF-β signaling include [8](https://doi.org/10.1038/s41573-020-0089-1):

• TGF-β receptor agonists: Small molecule activators promoting neuroprotective signaling
• Smad7 overexpression: Restoring inhibitory Smad function to reduce excessive TGF-β activity
• BMP agonists: Alternative pathway activation to promote neurogenesis
• Neutralizing antibodies: Blocking detrimental TGF-β effects in specific contexts
• kinase inhibitors: Targeting downstream signaling molecules

Clinical Considerations

Challenges in TGF-β-targeted therapy [9](https://doi.org/10.1016/j.tcb.2020.06.002):

• Pleiotropic effects: TGF-β has both protective and harmful effects depending on context
• BBB penetration: Delivery of large proteins to the brain remains challenging
• Dosing: Narrow therapeutic window requires careful titration
• Selectivity: Avoiding effects on peripheral tissues and immune function
• Timing: Optimal intervention point may vary by disease stage

• AAV-mediated gene delivery of Smad7
• Small molecule ALK5 inhibitors for specific contexts
• Brain-penetrant TGF-β neutralizing antibodies

Combination Therapies

Given the complex pathophysiology of CBS/PSP, TGF-β-targeted therapies may be most effective in combination:

• TGF-β + anti-tau: Combined pathway modulation with tau-targeted interventions
• TGF-β + neuroinflammation: Addressing both pathways simultaneously
• TGF-β + neurotrophic factors: Synergistic neuroprotective effects

Cross-Links to Related CBS/PSP Mechanisms

• [Neuroinflammation in CBS](/mechanisms/cbs-neuroinflammation) — TGF-β modulation of glial responses
• [4R Tauopathy Molecular Mechanisms](/mechanisms/4r-tau-cbs) — TGF-β/tau interactions
• [Cellular Senescence in CBS](/mechanisms/cbs-cellular-senescence) — TGF-β in cellular aging
• [TGF-beta Signaling in Neurodegeneration](/mechanisms/tgf-beta-signaling-neurodegeneration) — General pathway overview
• [BMP Signaling in Neurodegeneration](/mechanisms/tgf-beta-bmp-signaling-pathway) — Related TGF-β family signaling
• [GSK3-beta Signaling](/mechanisms/gsk3-beta-signaling) — Cross-talk with tau phosphorylation
• [Neurogenesis in Neurodegeneration](/mechanisms/neurogenesis-neurodegeneration) — TGF-β effects on neural stem cells

References